Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer

Bone

Volumn 18, Issue 6, 1996, Pages 531-537

  Rizzoli, R ^a,b   Forni, M ^b   Schaad, M A ^a   Slosman, D O ^c   Sappino, A P ^b   Garcia, J ^c   Bonjour, J P ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NONE   (Switzerland)

^c UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bisphosphonates; Bone metastasis; Bone mineral density; Breast cancer; Clodronate; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHLORAMBUCIL; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BONE RADIOGRAPHY; BONE REMODELING; BONE SCINTISCANNING; BREAST CANCER; CALCIUM URINE LEVEL; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; FEMUR NECK; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030176390     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(96)00075-0     Document Type: Article

References (43)

1. 1. Adami, H. O., Zack, M., Kressner, U., et al. Hip fractures in women with breast cancer. Am J Epidemiol 132:877-883; 1990.
2. 2. Biermann, W. A., Cantor, R. I., Fellin, F. M., et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone 12:S37-S42; 1991.
3. 3. Bijvoet, O. L. M., Morgan, D. B., and Fourman, P. The assessment of phosphate reabsorption. Clin Chim Acta 26:15-24; 1969.
4. 4. Bonjour, J. P., Guelpa, J., Bisetti, A., et al. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 9:123-130; 1988.
5. 5. Bonjour, J. P., Rizzoli, R., Ammann, P., et al. Bisphosphonates in clinical medicine. Bone Miner Res 8:205-264; 1994.
6. 6. Bruning, P. F., Pit, M. J., Jong-Bakker, M., et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308-310; 1990.
7. 7. Buchs, B., Rizzoli, R., and Bonjour, J. P. Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia. Bone 12:47-56; 1991.
8. 8. Buchs, B., Rizzoh, R., Slosman, D., et al. Densité minérale osseuse de la colonne lombaire, du col et de la diaphyse fémoraux d'un échantillon de la population genevoise. Schweiz Med Wochenschr 122:1129-1136; 1992.
9. 9. Coleman, R. E. and Rubens, R. D. The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66; 1987.
10. 10. Coleman, R. E., Woll, P. J., Miles, M., et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 58:621-625; 1988.
11. 11. Conte, P. F., Giannessi, P. G., Latreille, J., et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: A randomized, multicenter phase III trial. Ann Oncol 7:S41-S44; 1994.
12. 12. Delmas, P. D., Charbon, S., Chapuy, M. C., et al. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 4:163-168; 1982.
13. 13. Dempster, D. W. and Lindsay, R. Pathogenesis of osteoporosis. Lancet 34:797-801; 1993.
14. 14. Dodwell, D. J., Howell, A., and Ford, J. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. Br J Cancer 61:123-125; 1990.
15. 15. Elomaa, I., Blomqvist, C., Gröhn, P., et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1:146-149; 1983.
16. 16. Elomaa, I., Blomqvist, C., Porkka, L., et al. Treatment of skeletal disease in breast cancer: A controlled clodronate trial. Bone 8:S53-S56; 1987.
17. 17. Elte, J. W., Bijvoet, O. I. M., Cleton, F. J., et al. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 22:493-500; 1986.
18. 18. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944; 1991.
19. 19. Francini, G., Gonnelli, S., Petrioli, R., et al. Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591-598; 1992.
20. 20. Giannini, S., D'Angelo, A., Malvasi, L., et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141; 1993.
21. 21. Goldhirsch, A., Gelber, R. D., Price, K. N., et al. Effect of systemic adjuvant treatment of first sites of breast cancer relapse. Lancet 343:377-381; 1994.
22. 22. Jung, A., Chantraine, A., Donath, A., et al. Comparison of two parenteral diphosphonates in hypercalcaemia of malignancy. N Engl J Med 308:1499-1501; 1983.
23. 23. Lahtinen, R., Laakso, M., Palva, L, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049-1052; 1992.
24. 24. Martoni, A., Guaraldi, M., Camera, P., et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48:97-101; 1991.
25. 25. Morton, A. R., Cantrill, J. A., Pillai, G. V., et al. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. Br Med J 297:772-773; 1988.
26. 26. Neri, B., Gemelli, M. T., Sambataro, S., et al. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anti-Cancer Drugs 3:87-90; 1992.
27. 27. Nielsen, O. S., Munro, A. J., and Tannock, I. F. Bone metastases: Pathophysiology and management policy. J Clin Oncol 9:509-524; 1991.
28. 28. O'Rourke, N., McCloskey, E., Houghton, F., et al. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 13:929-934; 1995.
29. 29. Padmanabhan, N., Howell, A., and Rubens, R. D. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet ii:411-414; 1986.
30. 30. Paparella, P., Giorgino, R., Mancuso, S., et al. Oral continuous clodronate in the prevention of early postmenopausal bone loss. Current Ther Res 56:134-143; 1995.
31. 31. Paterson, A. H. G., Powles, T. J., Kanis, J. A., et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65; 1993.
32. 32. Pecherstorfer, M., Schilling, T., Janisch, S., et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 34:1039-1044; 1993.
33. 33. Redman, J. R., Bajorunas, D. R., Wong, G., et al. Bone mineralization in women following successful treatment of Hodgkin's disease. Am J Med 85:65-72; 1988.
34. 34. Rizzoli, R., Caverzasio, J., Bauss, F., et al. Inhibition of bone resorption by the bisphosphonate BM-21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein. Bone 13:321-325; 1992.
35. 35. Rossini, M., Gatti, D., Zamberlan, N., et al. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J. Bone Miner Res 9:1833-1837; 1994.
36. 36. Scher, H. I. and Yagoda, A. Bone metastases: Pathogenesis, treatment, and rationale for use of resorption inhibitors. Am J Med 82:6-28; 1987.
37. 37. Slosman, D. O., Rizzoli, R., Buchs, B., et al. Comparative study of the performances of X-ray and gadolinium 153 bone densitometers at the level of the spine, femoral neck and femoral shaft. Eur J Nucl Med 17:3-9; 1990.
38. 38. Storm, T., Thamsborg, G., Steiniche, T., et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271; 1990.
39. 39. Thiébaud, D., Leyvraz, S., Vonfliedner, V., et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 27:37-41; 1991.
40. 40. Vanholten, A. T. M., Bijvoet, O. L. M., Cleton, F. J., et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet ii:983-985; 1987.
41. 41. Vanholten, A. T. M., Kroon, H. M., Bijvoet, O. L. M., et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498; 1993.
42. 42. Watts, N. B., Harris, S. T., Genant, H. K., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79; 1990.
43. 43. WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva, 1979 (n° 48).